Phaseline

Targets › DRD4

DRD4 (Dopamine receptor D4): drug programs, companies and trials

17 programs from 16 companies in 37 trials: 17 Phase 2, 14 Phase 3, 3 Phase 1, 3 Phase 4; Neurology, Psychiatry, Cardiovascular; next expected readout Nov 2026.

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. In addition to dopamine, also activated by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs. (UniProt, P21917)

Open in Phaseline: the race on DRD4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dennis M. McNamara, MD, MSBromocriptine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Peripartum Cardiomyopathy, PostpartumJun 2028
Massachusetts General HospitalPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Adrenoleukodystrophy–
Jimma UniversityBromocriptine mesylate
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Dilated CardiomyopathyNov 2026
Daniel LindqvistPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Bipolar Disorder (BD)Dec 2029
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsApomorphine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Idiopathic Parkinson's Disease–
I.R.C.C.S. Fondazione Santa LuciaRotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Alzheimer Disease–
University of California, San DiegoPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Anxiety DisordersNov 2026
University of LiegeApomorphine Hydrochloride
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Disorder of ConsciousnessDec 2026
M.D. Anderson Cancer CenterChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 2DeliriumFeb 2027
M.D. Anderson Cancer CenterHaloperidol
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist
HTR2A, DRD2, DRD3, DRD4Phase 2Delirium; Advanced Malignant Neoplasm; Advanced CancersFeb 2027
Boryung PharmaceuticalOlanzapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy …May 2027
Clinical Academic Center (2CA-Braga)Pramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Obsessive-Compulsive DisorderAug 2028
University Hospital, Rouenrotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Kidney DiseasesJul 2030
Stanford UniversityPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Depression - Major Depressive DisorderAug 2030
Md. Moktadirul Hoque ShuvoTrifluoperazine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Functional Dyspepsia–
Serina TherapeuticsSER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027
Capital Medical UniversityChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 1Acute Ischemic Stroke–

Conditions

Delirium (3) Schizophrenia (2) Advanced Malignant Solid Neoplasm (2) Multiple Myeloma (2) PARKINSON DISEASE (Disorder) (1) Advanced Malignant Neoplasm (1) Advanced Cancers (1) Schizophrenia and Related Disorders (1) Chemotherapy Induced Nausea and Vomiting (1) Oncology Patients Receiving Chemotherapy (1) Electroacupuncture (1) Advanced Cancer (1)

Modalities

small molecule (16), protein or peptide (1)

Companies

M.D. Anderson Cancer Center (2) Serina Therapeutics (1) Boryung Pharmaceutical (1) University of Liege (1) Md. Moktadirul Hoque Shuvo (1) Daniel Lindqvist (1) Stanford University (1) University Hospital, Rouen (1) University of California, San Diego (1) Jimma University (1) I.R.C.C.S. Fondazione Santa Lucia (1) MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1) Massachusetts General Hospital (1) Clinical Academic Center (2CA-Braga) (1) Capital Medical University (1) Dennis M. McNamara, MD, MS (1)

Related targets

DRD2 (17) DRD3 (17) HTR2A (5) HTR2C (2) DRD1 (1) DRD5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.